<SEC-DOCUMENT>0001157523-14-001750.txt : 20140430
<SEC-HEADER>0001157523-14-001750.hdr.sgml : 20140430
<ACCEPTANCE-DATETIME>20140430162129
ACCESSION NUMBER:		0001157523-14-001750
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140430
FILED AS OF DATE:		20140430
DATE AS OF CHANGE:		20140430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICON PLC
		CENTRAL INDEX KEY:			0001060955
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				981067160

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-08704
		FILM NUMBER:		14799068

	BUSINESS ADDRESS:	
		STREET 1:		SOUTH COUNTY BUSINESS PARK
		STREET 2:		LEOPARDSTOWN
		CITY:			DUBLIN 18
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00 353 1 291 2000

	MAIL ADDRESS:	
		STREET 1:		SOUTH COUNTY BUSINESS PARK
		STREET 2:		LEOPARDSTOWN
		CITY:			DUBLIN 18
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ICON PLC  /ADR/
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a50854561.htm
<DESCRIPTION>ICON PLC 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font><br><br><br><font style="font-size: 12pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><br><font style="font-size: 12pt">Washington,
      D.C. 20549</font><br><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Report
      of Foreign Private Issuer</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Rule 13a-16 under</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>the
      Securities Exchange Act of 1934</b></font><br><br><br>For the month ended<font style="font-size: 10pt; font-family: Times New Roman">
      April, 2014</font><br><br><br><font style="font-size: 18pt; font-family: Times New Roman"><b>ICON&#160;plc</b></font><br>(R<font style="font-size: 10pt; font-family: Times New Roman">egistrant's
      name)</font><br><br><br>0-29714<br>(Commission file number)<br><br><br>South
      County Business Park, Leopardstown, Dublin 18, Ireland<br>(Address of
      principal executive offices)<br><br>Brendan Brennan, CFO<br>South County
      Business Park Leopardstown, Dublin 18, Ireland.<br>Brendan.Brennan@iconplc.com<br>0011-353-1-291-2000<br>(Name,
      telephone number, email and/or facsmile number and address of Company
      contact person)<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant files or will file annual
      reports under cover Form 20-F or Form 40-F.<br>
    </p>
    <p style="text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<u><b>X</b></u>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<b>_</b>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(1):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(7):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant by furnishing the
      information contained in this Form is also thereby furnishing the
      information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<b>_</b>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p style="white-space: nowrap">
      If &quot;Yes&quot; is marked, indicate below the file number assigned to the
      registrant in connection with Rule 12g3-2(b):82&#160;&#160;&#160;&#160;&#160;&#160;<b>N/A</b><br><br>
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>
      <u><font style="font-size: 10pt"><b>EXHIBIT&#160;LIST</b></font></u><br>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Exhibit</u>
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 2%; text-align: left">
          &#160;
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 20%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>Description</u>
          </p>
        </td>
        <td style="width: 72%">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 2%">

        </td>
        <td style="width: 20%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 72%; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; white-space: nowrap; text-align: left; padding-right: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td style="width: 2%">

        </td>
        <td colspan="2" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            ICON plc Press Release issued April 30, 2014 - ICON&#160;Announces
            Appointment of Dr. Hugh Brady to Board of Directors.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="width: 100%; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>
      <font style="font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 40%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>ICON plc</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 40%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 5%; text-align: left">
          Date:
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 55%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            April 30, 2014
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 40%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u>/s/ Brendan Brennan</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 40%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Brendan Brennan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 40%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50854561_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2014 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>ICON
      Announces Appointment of Dr. Hugh Brady to Board of Directors</b></font>
    </p>
    <p>
      DUBLIN--(BUSINESS WIRE)--April 30, 2014--ICON plc,<b> (NASDAQ: ICLR), </b>a
      global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries, today
      announced the appointment of Dr. Hugh Brady as a non-executive director.
    </p>
    <p>
      Dr. Brady is President Emeritus of University College Dublin (UCD), one
      of Europe&#8217;s leading research-intensive universities, where he served as
      President from 2004 until the end of 2013. During his tenure Dr. Brady
      oversaw a significant expansion of UCD&#8217;s science, engineering and
      biomedical research capacity, including the development of the Conway
      Institute for Biomedical Research, UCD Clinical Research Centre and the
      Dublin Academic Medical Centre. In addition, he led a major growth in
      UCD&#8217;s international footprint, including the establishment of the
      Beijing-Dublin International College and the UCD Shenzhen Health
      Sciences Institute in China.
    </p>
    <p>
      A nephrologist by training, Dr. Brady was Professor of Medicine and
      Therapeutics at UCD before being appointed the university&#8217;s President.
      He returned to Ireland having built a successful career as a physician
      and biomedical research scientist in the US, where he spent nine years
      at Harvard University, including a period as Associate Professor of
      Medicine. In parallel with his academic career at Harvard, he served as
      Director of the Renal Division of the Brockton/West Roxbury VA Medical
      Center and Consultant Physician at the Brigham and Women&#8217;s Hospital,
      Boston. He has an international reputation in the pathogenesis of
      diabetic kidney disease and renal inflammation.
    </p>
    <p>
      Dr. Brady has held many national and international leadership roles,
      including Chairman of the Irish Health Research Board and Chairman of
      the Universitas 21 Network of global research universities. He is also a
      non-executive director of Kerry Group plc.
    </p>
    <p>
      <i>&#8220;I am very pleased that Dr Brady has joined the board&#8221;</i>
      commented Mr. Thomas Lynch, Chairman. <i>&#8220;His inspirational leadership
      of UCD, Irelands&#8217; largest university, during the past ten years,
      extensive international experience, especially in Asia coupled with a
      distinguished career as an academic clinician in Ireland and the United
      States will bring invaluable experience and expertise to ICON.&#8221;</i>
    </p>
    <div style="width: 100%; text-indent: 0pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      This press release contains forward-looking statements. These statements
      are based on management's current expectations and information currently
      available, including current economic and industry conditions. These
      statements are not guarantees of future performance or actual results,
      and actual results, developments and business decisions may differ from
      those stated in this press release. The forward-looking statements are
      subject to future events, risks, uncertainties and other factors that
      could cause actual results to differ materially from those projected in
      the statements, including, but not limited to, the ability to enter into
      new contracts, maintain client relationships, manage the opening of new
      offices and offering of new services, the integration of new business
      mergers and acquisitions, as well as economic and global market
      conditions and other risks and uncertainties detailed from time to time
      in SEC reports filed by ICON, all of which are difficult to predict and
      some of which are beyond our control. For these reasons, you should not
      place undue reliance on these forward-looking statements when making
      investment decisions. The word &quot;expected&quot; and variations of such words
      and similar expressions are intended to identify forward-looking
      statements. Forward-looking statements are only as of the date they are
      made and we do not undertake any obligation to update publicly any
      forward-looking statement, either as a result of new information, future
      events or otherwise. More information about the risks and uncertainties
      relating to these forward-looking statements may be found in SEC reports
      filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
      available on the SEC's website at <u>http://www.sec.gov</u>.
    </p>
    <p>
      ICON plc is a global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries. The company
      specialises in the strategic development, management and analysis of
      programs that support clinical development - from compound selection to
      Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
      currently, operates from 76 locations in 37 countries and has
      approximately 10,300 employees. Further information is available at <u>www.iconplc.com</u>.
    </p>
    <p>
      Source: ICON plc
    </p>
    <p>
      All at ICON.
    </p>
    <p>
      <b>ICON/ICLR-F</b>
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>ICON plc<br>Investor Relations<br>1-888-381-7923<br>or<br>Brendan
      Brennan<br>Chief Financial Officer<br>+ 353 &#8211;1-291-2000<br>or<br>Simon
      Holmes<br>EVP Investor Relations and Corporate Development<br>+ 353
      &#8211;1-291-2000
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
